Corient Private Wealth LLC Purchases 174,936 Shares of Veeva Systems Inc. (NYSE:VEEV)

Corient Private Wealth LLC boosted its position in Veeva Systems Inc. (NYSE:VEEV) by 1,281.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 188,591 shares of the technology company’s stock after acquiring an additional 174,936 shares during the period. Corient Private Wealth LLC’s holdings in Veeva Systems were worth $39,651,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its holdings in shares of Veeva Systems by 138.9% in the 3rd quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock worth $457,366,000 after purchasing an additional 1,267,061 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Veeva Systems in the third quarter valued at $526,000. Metis Global Partners LLC grew its holdings in shares of Veeva Systems by 13.1% during the third quarter. Metis Global Partners LLC now owns 5,057 shares of the technology company’s stock valued at $1,061,000 after buying an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC grew its holdings in shares of Veeva Systems by 7.3% during the third quarter. OneDigital Investment Advisors LLC now owns 1,909 shares of the technology company’s stock valued at $401,000 after buying an additional 130 shares during the last quarter. Finally, CIBC Asset Management Inc raised its holdings in shares of Veeva Systems by 5.5% in the 3rd quarter. CIBC Asset Management Inc now owns 5,641 shares of the technology company’s stock worth $1,184,000 after acquiring an additional 294 shares during the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on VEEV shares. Canaccord Genuity Group lifted their price target on Veeva Systems from $210.00 to $270.00 and gave the company a “hold” rating in a research note on Friday, December 6th. Robert W. Baird upped their price target on Veeva Systems from $283.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, March 6th. KeyCorp dropped their price objective on Veeva Systems from $285.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Mizuho began coverage on shares of Veeva Systems in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $275.00 target price for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of Veeva Systems from $208.00 to $218.00 and gave the company a “neutral” rating in a report on Monday, December 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $255.28.

Veeva Systems Stock Up 1.2 %

NYSE VEEV opened at $236.93 on Tuesday. The company has a market cap of $38.47 billion, a PE ratio of 58.50, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. Veeva Systems Inc. has a 52 week low of $170.25 and a 52 week high of $258.93. The firm’s 50-day simple moving average is $227.61 and its two-hundred day simple moving average is $221.69.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.